Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells

Bibliography

• EHRLICH P: Collected studies on immunity. Vol. II, John Wiley, New York. (1906).
   Google Scholar
• HIMMELWEIT B: The collected papers of Paul Ehrlich. Pergamon Press, Oxford (1975).
   Google Scholar
• KUFE DW, NADLER L, SARGENT L et al.: Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res. (1983) 43:851–857.
   PubMed Web of Science ®Google Scholar
• HAKOMORI S, KANAGI R: Glycosphingolipids as tumor-associated and differentiation markers. j Natl. Cancer Inst. (1983) 71:231–251.
   PubMed Web of Science ®Google Scholar
• AZIZ KJ, MAMIM PE, HACKETT JL, TSAKERIS TM: Perspectives in laboratory management. Tumor markers: the premarket review and approval process. Am. Clin. Lab. (1993) 1:13–15.
   Google Scholar
• POTTER VR: On the road to the blocked ontogeny theory. Adv. Oricol. (1988) 4:1–8.
   Google Scholar
• CHO-CHUNG YS: Site-selective 8-chloro-cyclic adenosine 3',5'-monophosphate as a biologic modulator of cancer: restoration of normal control mechanisms. j Natl. Cancer Inst. (1989) 81:982–987.
   PubMed Web of Science ®Google Scholar
• RITTENHOUSE HG, MANDERINO GL,HASS GM: Mucin-type glycoproteins as tumor markers. Lab. Med. (1985) 16:556–560.
   Google Scholar
• FEIZI T: Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are oncodevelopmental antigens. Nature (1985) 314:53–57.
   PubMed Web of Science ®Google Scholar
• REISFELD RA, CHERESH DA: Human tumor antigens. Adv. Immuriol. (1987) 40:323-377. LLOYD KO, OLD LJ: Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res. (1989) 49:3445–3451.
   Google Scholar
• GREINER JW, ULLMANN CD, NIERODA C etal.: Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (1311-CC49) when given in combination with gamma-interferon. Cancer Res. (1993) 53:600–608.
   Google Scholar
• HUEBNER RJ, TODARO GJ: Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl. Acad. Sci. USA (1969) 64:1087–1094.
   PubMed Web of Science ®Google Scholar
• DARLINGTON DC: The plasmagene theory of the origin of cancer. Br. I Cancer (1948) 2:118–126.
   PubMed Web of Science ®Google Scholar
• KELLY K, SIEBENLIST U: The regulation and expression of c-myc in normal and malignant cells. Ann. Rev Immuriol. (1986) 4:317–338.
   PubMed Web of Science ®Google Scholar
• BISHOP JM, BAKER B, FUJITA D et al.: Genesis of a virus-transforming gene. Natl. Cancer Inst. Monogr. (1978) 48:219–223.
   PubMedGoogle Scholar
• BISHOP JM: Oncogenes. Scientific American (1982) 246:80–90.
   PubMedGoogle Scholar
• BISHOP JM: The molecular genetics of cancer. Science (1987) 235:303–311.
   Web of Science ®Google Scholar
• KARESS RE, HAYWARD WS, HANAFUSA H: Transforming protein encoded by the cellular information of recovered avian sarcoma viruses. Cold Spring Harbor Symp. Quark. Biol. (1979) 44:765–771.
   Google Scholar
• KLEIN G: The role of gene dosage and genetic transpositions in carcinogenesis. Nature (1981) 294:313–318.
   PubMed Web of Science ®Google Scholar
• EVA A, ROBBIN KC, ANDERSEN PR et al.: Cellular genes analogues to retroviral onc genes are transcribed in human tumour cells. Nature (1982) 295:116–119.
   PubMed Web of Science ®Google Scholar
• INGRAHAM CA, COX ME, WARD DC, FULTS DW, MANESS PF: c-src and other proto-oncogenes implicated in neuronal differentiation. Ma. Chem. Neuropathol. (1989) 10:1–14.
   PubMedGoogle Scholar
• DALLA-FAVERA R, BREGNI M, ERIKSON J, PATTERSON D, GALLO RC, CROCE CM: Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sd. USA (1982) 79:7824–7827.
   PubMed Web of Science ®Google Scholar
• DALLA-FAVERA R, MARTINOTTI S, GALLO RC, ERIKSON J, CROCE CM: Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science (1983) 219:963–967.
   PubMed Web of Science ®Google Scholar
• MAHALEY MS, GILLESPIE GY: Immunologic considerations of patients with brain tumors. In: Oncology of the nervous system. Walker MD (Ed.), Boston, The Hague, Dordrecht, Lancaster: Martinus Nijhoff Publishers, The Netherlands, (1983):151–164.
   Google Scholar
• JAKOBOVITS A: The expression of growthfactors and growth factor receptors during mouse embryogenesis. In: Oncogenes and Growth control. P Kahn, T Graf (Eds.), Springer Verlag, Berlin-New York-Tokyo (1986):9–17.
   Google Scholar
• SPORN MB, ROBERTS AB: Autocrine growth factors and cancer. Nature (1985) 313:745–747.
   PubMed Web of Science ®Google Scholar
• MURRAY AW, KIRSCHNER MW: Cyclinsynthesis drives the early embryonic cell cycle. Nature (London) (1989) 339:275–280.
   PubMed Web of Science ®Google Scholar
• HALL FL, VULLIET PR: Proline-directed protein phosphorylation. Curr. Opin. Cell Biol. (1991) 3:176–184.
   PubMed Web of Science ®Google Scholar
• GAZIT A, IGARISHI H, CIU IM: Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation. Cell (1984) 39:89–97.
   PubMedGoogle Scholar
• GLICK RE GETTLEMAN R, PATEL K, KIRTIKUMAR P, LAKSHMAN R, TSIBRIS JCM: Insulin and insulin-like growth factor 1 in brain tumors. Binding and in vitro effects. Neurosurgery (1989) 24:791–797.
   Google Scholar
• FLEMING TI MATSUI T, AARONSON SA: Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy. Exp. Cerontol. (1992) 27:523–532.
   PubMed Web of Science ®Google Scholar
• HENRIKSEN R, FUNA K, WILANDER E, BACKSTROM T, RIDDERHEIM M, OBERG K: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. (1993) 53:4550–4554.
   PubMed Web of Science ®Google Scholar
• BAR-SAGI D, FERAMISCO J: Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell (1985) 42:841–848.
   PubMed Web of Science ®Google Scholar
• NODA M, KO M, OGURA A et al.: Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neural cell line. Nature (1985) 318:73–75.
   PubMed Web of Science ®Google Scholar
• HAGAG N, HALEGOUA S, VIOLA M: Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21. Nature (1986) 319:680–682.
   PubMed Web of Science ®Google Scholar
• TAGLIAFERRI P, CARAGLIA M, MURARO R et al.: Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. Anti-Cancer Drugs (1994) 5:379–393.
   PubMed Web of Science ®Google Scholar
• SPORN MB, TODARO GJ: Autocrine secretion and malignant transformation of cells. N Engl. J. Med. (1980) 308:878–880.
   Google Scholar
• SPORN MB, TODARO GJ: Autocrine growth factors and cancer. Nature (1985) 313:747–751.
   Web of Science ®Google Scholar
• KOHLER G, MILSTEIN C: Continuousculture of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• SONGSIVILAI S, LACHMANN PJ: Antibody engineering: current status and future development. Asian Pacific I. Allergy Immunol. (1990) 8:53–60.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
   Google Scholar
• HOUGHTON AN, SCHEINBERG DA: Monoclonal antibodies: potential applications to the treatment of cancer. Semir]. Oncol. (1986) 13:165–179.
   PubMed Web of Science ®Google Scholar
• COIFFIER B: Monoclonal antibodies in the treatment of neoplastic hematologic diseases. Bull. Cancer (2000) 87:839–845.
   PubMed Web of Science ®Google Scholar
• •Important paper reviewing the possibilities for the employment of cancer cell-directed immunotherapy in the treatment of non-solid malignancies.
   Google Scholar
• PENAULT-LLORCA FM, BALATON AJ. Monoclonal antibodies in oncology: applications in diagnosis, prognosis and prediction of response to therapy on tissue specimens. Bull. Cancer (2000) 87:794–803.
   Google Scholar
• ••Thoroughly reviews the importance ofimmunohistochemistry in the initial and differential diagnosis of cancer.
   Google Scholar
• GABRILOVE JL: Differentiation factors. &min. Oncol. (1986) 13:228–233.
   Google Scholar
• TALMADGE JE, HERBERMAN RB: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat. Rep. (1986) 70:171–182.
   PubMedGoogle Scholar
• SKERRA A, PLUCKTHUN A: Assembly of a functional immunoglobulin Fy fragment in Escherichia coli. Science (1988) 240:1038–1041.
   PubMed Web of Science ®Google Scholar
• BETTER M, CHANG CP, ROBINSON RR, HORWITZ AH: Escherichia coli secretion of an active chimeric antibody fragment. Science (1988) 240:1041–1043.
   PubMed Web of Science ®Google Scholar
• RIECHEMANN L, FOOTE J, WINTER G: Expression of an antibody Fy fragment in myeloma cells. I Md. Biol. (1988) 203:825–828.
   PubMed Web of Science ®Google Scholar
• LEVY R, MILLER RA, STRATTE PT: Therapeutic trials of monoclonal antibody in leukemia and lymphoma: biologic considerations. In: MonoclonalAntibod/es and Cancer Boss BD, Langman R, Trowbridge I etal. (Eds.), Academic Press, Orlando, Florida, USA (1983):5–16.
   Google Scholar
• HERLYN D, LUBECK M, SEARS H, KOPROWSKI H: Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. I Immunol. Methods (1985) 85:27–38.
   PubMed Web of Science ®Google Scholar
• WONG JH, IRIE RF, MORTON DL: Human monoclonal antibodies: prospects for the therapy of cancer. Sem. Surgical Oncol. (1989) 5:448–452.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI H, FURUKAWA K, FORTUNATO SR et al.: Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA (1987) 84:2416–2420.
   PubMed Web of Science ®Google Scholar
• CHERESH DA, HARPER JR, SCHULZG. REISFELD RA: Localization of the Expert Op/n. Biol. Ther. (2001) 1(4) gangliosides GD3 and GD2 in adhesion plaques and on the surface of human melanoma cells. Proc. Nati Acad. Li. USA (1984) 81:5767–5771.
   Google Scholar
• CHEUNG N-KV, SAARINEN UM, NEELY JE, LANDMEIER B, DONOVAN D, COCCIA PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. (1985) 45:2642–2649.
   PubMed Web of Science ®Google Scholar
• IMAM A, MITCHELL MS, MODLIN RL, TAYLOR CR, KEMPF RA, KAN-MITCHELL J: Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections. j Invest. Dermatol. (1986) 86:145–148.
   PubMed Web of Science ®Google Scholar
• KAN-MITCHELL J, IMAM A, KEMPF RA, TAYLOR CR, MITCHELL MS: Human monoclonal antibodies directed against melanoma tumor-associated antigens. Cancer Res. (1986) 46:2490–2496.
   PubMed Web of Science ®Google Scholar
• JAMES K, BELL GT: Human monoclonal antibody production current status and future prospects. j Inunutiol. Methods (1987) 100:5–40.
   PubMed Web of Science ®Google Scholar
• THOMPSON KM: Human monoclonal antibodies. Inunutiol. Today (1988) 9:113–117.
   PubMedGoogle Scholar
• JERNE NK: Towards a network theory ofthe immune system. Ann. Inunutiol. (Paris). (1974) 125:373–389.
   Google Scholar
• LUDWIG DS, FINKELSTEIN RA, KARU AE, DALLAS WS, ASHBY ER SCHOOLNIK GK: Anti-idiotypic antibodies as probes of protein active sites: Application to cholera toxin subunit B. Proc. Nati Acad. Sci. USA (1987) 84:3673–3677.
   PubMed Web of Science ®Google Scholar
• HERLYN D, WETTENDORFF M, ILIOPOULOS D, KOPROWSKI H: Functional mimicry of tumor-associated antigens by antiidiotypic antibodies. Exper. Cilia. Inunutiogenet. (1988) 5:165–175.
   PubMedGoogle Scholar
• O'CONNELL MJ, CHEN ZJ, YANG H et al.: Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. Semi]. Surg. Olga (1989) 5:441–447.
   Google Scholar
• LEVY R, MILLER RA: Therapy of lymphoma directed at idiotypes. Monogr. Natl. Cancer Inst. (1990) 10:61–68.
   PubMedGoogle Scholar
• MILLER RA, MALONEY DG, WARNKE R, LEVY R: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl. J Med. (1982) 306:517–522.
   PubMed Web of Science ®Google Scholar
• MEEKER TC, LOWDER J, MALONEY DG et all: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 65:1349–1363.
   PubMed Web of Science ®Google Scholar
• RAFFELD M, NECKERS L, LONGO DL, COSSMAN J: Spontaneous alteration of idiotype in a monoclonal B cell lymphoma: escape from the detection by anti-idiotype. N Engl. j Med. (1985) 312:1653–1658.
   PubMed Web of Science ®Google Scholar
• NADLER LM, STASHENKO E HARDY R et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. (1980) 40:3147–3154.
   Google Scholar
• NEUBERGER MS, REJEWSKY K: Switch from hapten-specific immunoglobulin M to immunoglobulin D secretion in a hybrid mouse cell line. Proc. Nail. Acad. Li. USA (1981) 78:1138–1142.
   PubMed Web of Science ®Google Scholar
• CAP ONE PM, PAPSIDERO LD, CHU TM: Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. Nail. Cancer Inst. (1984) 72:673–677.
   PubMed Web of Science ®Google Scholar
• LIU MA, KRANZ DM, KURNICK JT, BOYLE LA, LEVY R, EISEN HN: Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc. Nail. Acad. Sci. USA (1985) 82:8648–8652.
   PubMed Web of Science ®Google Scholar
• PEREZ P, HOFFMAN RW, SHAW S, BLUESTONE JA, SEGAL DM: Specific targeting of cytotoxic T cells by anti-T3 linking to anti-target cell antibody. Nature (1985) 316:354–356.
   PubMed Web of Science ®Google Scholar
• NOLAN 0, O'KENNEDY R: Bifunctional antibodies: concept, production and applications. Biochlin. Biophys. Acta. (1990) 1040:1–11.
   PubMed Web of Science ®Google Scholar
• NOLAN 0, O'KENNEDY R: Bifunctionalantibodies and their potential clinical applications. Int. j Clin. Lab. Med. (1992) 22:21–27.
   Google Scholar
• FANGER MW, SEGAL DM, ROMET-LEMONNE J: Bispecific antibodies and targeted cellular cytotoxicity. konutiol. Today (1991) 12:51–54.
   Google Scholar
• MILSTEIN C, CUELLO AC: Hybrid hybridomas and their use in immunohistochemistry. Nature (1983) 305:537–540.
   PubMed Web of Science ®Google Scholar
• BARR IG, MacDONALD HR, BUCHEGGER F, VON FLIEDNER V: Lysis of tumour cells by the retargeting of murine cytotoxic T lymphocytes with bispecific antibodies. Int. j Cancer (1987) 40:423–429.
   PubMed Web of Science ®Google Scholar
• MENARD S, CANEVARI S, COLNAGHI MI: Hybrid antibodies in cancer diagnosis and therapy. Int. j Biol. Markers (1989) 4:131–134.
   Google Scholar
• NITTA T, SATO K, YAGITA H,OKUMURA K, ISHII S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet (1990) 335:368–374.
   PubMed Web of Science ®Google Scholar
• SHALABY MR, SHEPARD HM, PRESTA L et al.: Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. j Exp. Med. (1992) 175:217–225.
   PubMed Web of Science ®Google Scholar
• YE D, MENDELSOHN J, FAN Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene (1999) 18:731–738.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. (1997) 3:2703–2707.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. (1999) 5:909–916.
   PubMed Web of Science ®Google Scholar
• HNATOWICH DJ, LAYNE WW, CHILDS RL et al.: Radioactive labeling of antibody: a simple and efficient method. Science (1983) 220:613–615.
   PubMed Web of Science ®Google Scholar
• SHAH SA, GALLAGHER BM, SANDS H: Radioimmunodetection of small human tumor xenografts in spleen of athymic mice by monoclonal antibodies. Cancer Res. (1985) 45:5824–5829.
   PubMed Web of Science ®Google Scholar
• ILLIDGE TM, BROCK S: Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Cun Pim= Design (2000) 6:1399–1418.
   Google Scholar
• ••Provides a thorough and up-to-date reviewof the methods and limitations of this approach to targeted antineoplastic therapy.
   Google Scholar
• VUILLEZ JP: Radioimmunotargeting: diagnosis and therapeutic use. Bull. Cancer (2000) 87:813–827.
   PubMed Web of Science ®Google Scholar
• JURCIC JG: Antibody immunotherapy for leukemia. Cun Oncol. Rep. (2000) 2:114–122.
   PubMedGoogle Scholar
• SANDS H, LOVELESS SE: Biodistribution and pharmacokinetics of recombinant, human interleukin-2 in mice. Int. J. Immunopharmacol. (1989) 11:411–
   PubMed Web of Science ®Google Scholar
• ANDRES RY, SCHUBIGER PA: Radiolabeling of antibodies. Methods and limitations. Nukl. Med. (1986) 25:162–166.
   PubMedGoogle Scholar
• RAMJEESINGH M., ZYWULKO M, ROTHSTEIN A, WHYTE R, SHAMI EY: Antigen protection of monoclonal antibodies undergoing labelling. J. bronurrol Methods (1990) 133:159–167.
   PubMed Web of Science ®Google Scholar
• BRITTON KE, MATHER SJ, GRANOWSKA M: Radiolabelled monoclonal antibodies in oncology. III. Radiohronurrotherapy. Nucl. Med. Corronurricat. (1991) 12:333–347.
   Google Scholar
• GOLDENBERG DM, DeLAND FH, KIMM EE et al.: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse tumors by external photoscanning. N Engl. J. Med. (1978) 298:1384–1388.
   PubMed Web of Science ®Google Scholar
• MACH JP, CARREL S, FORNI M, RITSCHARD J, DONATH A, ALBERTO P: Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma. N Engl. J. Med. (1980) 303:5–10.
   PubMed Web of Science ®Google Scholar
• MACH JP, CARREL S, MERENDA C, SORDAT B, CEROTTINI JC: hi vivo localization of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (1974) 248:704–706.
   PubMed Web of Science ®Google Scholar
• MACH JP, CHATAL JF, LUMBROSO J-D et al.: Tumor localization in patients by radiolabeled monoclonal antibody against colon carcinoma. Cancer Res. (1983) 43:5593–5600.
   PubMed Web of Science ®Google Scholar
• EPENETOS AA, MATHER S, GRANOWSKA M: Targeting of iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumors. Lancet (1982) 2:999–1005.
   PubMed Web of Science ®Google Scholar
• FARRANDS PA, PIMM MV, EMBLETON MJ etal.: Radioimmunodetection of human colorectal cancers by an antitumor monoclonal antibody. Lancet (1982) 2:397–404.
   Google Scholar
• FAIRWEATHER DS, BRADWELL AR, DYKES PW, VAUGHAN AT, WATSON-JAMES SF, CHANDLER S: Improved tumor localization using indium-" labelled antibodies. Br Med. J. (1983) 287:167–170.
   PubMed Web of Science ®Google Scholar
• MOLDOFSKY PJ, POWE J, MULHERN CB et al.: Metastatic colon carcinoma detected with radiolabeled F(ab')2 monoclonal antibody fragments. Radiology (1983) 149:549–555.
   PubMed Web of Science ®Google Scholar
• CHATAL JF, SACCAVINI JC, FUMOLEAU P et al: Immunoscintigraphy of colon carcinoma. J. Nucl. Med. (1984) 25:307–314.
   PubMed Web of Science ®Google Scholar
• DILLMAN R: Monoclonal antibodies in the treatment of cancer. CRC Crit. Rev. Oricol/Hernatol (1984) 1:357–385.
   Google Scholar
• MOLDOFSKY PJ, SEARS HF, MULHERN CB JR. et al: Detection of metastatic tumor in normal sized retroperitoneal lymph nodes by monoclonal antibody imaging. N Engl. J. Med. (1984) 311:106–107.
   Google Scholar
• DELALOYE B, DELALOYE-BISCHOF A, DUDCZAK R etal.: Clinical comparison of 99mTc-HMDP and 99mTc-MDP. A multicenter study. Eur. J. Nucl. Med. (1985) 11:182–185.
   Google Scholar
• DELALOYE B, BISCHOF-DELALOYE A, BUCHEGGER F et al: Detection of colorectal carcinoma by emission-computerized tomography after injection of 123-iodine labeled Fab or Rab)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J. Clirr. Invest. (1986) 77:301–311.
   PubMed Web of Science ®Google Scholar
• RAINSBURY RM, WESTWOOD JH, COOMBES RC: Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-M. Lancet (1983) 2:934–938.
   PubMed Web of Science ®Google Scholar
• LARSON SM, BROWN JP, WRIGHT P, CARRASQUILLO JA, HELLSTROM I, HELLSTROM KE: Imaging of melanoma with 131-I-labeled monoclonal antibodies. J. Nucl. Med. (1983) 24:123–129.
   PubMed Web of Science ®Google Scholar
• LARSON SM, CARRASQUILLO JA, KROHN KA et al.: Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies. JAMA (1983) 249:811–812.
   PubMed Web of Science ®Google Scholar
• LARSON SM, CARRASQUILLO JA, KROHN KA et al: Localization of 1311-labeled p96-specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clirr. Invest. (1983) 72:2101–2114.
   PubMed Web of Science ®Google Scholar
• HALPERN SE, DILLMAN RO, WITZTUM KF: Radioimmunodetection of melanoma using 11'In 96.5 monoclonal antibody: a preliminary report. Radiology (1985) 155:493–499.
   Google Scholar
• MURRAY JL, ROSENBLUM MG, SOBOL RE et al: Radioimmunoimaging in malignant melanoma with "In-labeled monoclonal antibody 96.5. Cancer Res. (1985) 45:2376–2381.
   PubMed Web of Science ®Google Scholar
• ROSENBLUM MG, MURRAY JL, HAYNIE TP et al: Pharmacokinetics of In-"-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res. (1985) 45:2382–2386.
   PubMed Web of Science ®Google Scholar
• BURAGGI GL, CALLEGARO L, MARIANI G etal.: Imaging with I-131-labeled monoclonal antibodies to a high molecular weight melanoma-associated antigen in patients with melanoma: efficiency of whole immunoglobulin and its F (ab')2 fragments. Cancer Res. (1985) 45:3378–3387.
   Google Scholar
• GREINER JW, GUADAGNI F, ROSELLI M, ULLMANN CD, NIERODA C, SCHLOM J: Improved experimental radioimmunotharapy of colon xenografts by combining 131I-CC49 and interferon-gamma. Diseas. Col. Rect. (1994) 37:S100–S105.
   PubMed Web of Science ®Google Scholar
• HARTMANN F, HORAK EM, GARMESTANI K et al.: Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi_ anti-Tac. Cancer Res. (1994) 54:4362–4370.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, KITAMURA K, NISHIDA S et al: Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study. Surg. Today (1999) 29:190–193.
   PubMed Web of Science ®Google Scholar
• BERCHE C, MACH JP, LUMBROSO JD etal.: Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br. Med. J. (1982) 285:1447–1451.
   Google Scholar
• MACH JP, BUCHEGGER F, FORNI Met al.: Immunoscintigraphy of human carcinoma after injection of radiolabeled monoclonal anti-carcinoembryonic antigen antibodies. Curr. Top. ll/licrobiol. brunurrol. (1983) 104:49–55.
   Google Scholar
• CASELLAS P, BROWN JP, GROS 0 et al: Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. hit. J. Cancer (1982) 30:437–443.
   PubMed Web of Science ®Google Scholar
• BURNOL TF, WANT QC, REISFELD RA, KAPLAN NO: Monoclonal antibody Expert Op/n. Biol. Ther. (2001) 1(4) and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. Mioli (1983) 80:529–533.
   Google Scholar
• TROWBRIDGE IS, DOMINGO D: Anti-transferrin monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature (1981) 294:171–173.
   PubMed Web of Science ®Google Scholar
• WATANABE Y, MIYAZAKI H, OSAWA T: Effect of a monoclonal anti-carcinoembryonic antigen antibody-ricin A-chain conjugate on human carcinoembryonic antigen-producing tumor cells. I Pharm. Dyn. (1984) 7:593–603.
   PubMedGoogle Scholar
• GRIFFIN TW, HAYNES LR, DEMARTINO JA: Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line. 1 Natl. Cancer Inst. (1982) 69:799–805.
   PubMed Web of Science ®Google Scholar
• VALLERA DA, ASH RC, ZANJANI ED et al.: Anti-T cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies. Science (1983) 222:512–515.
   PubMed Web of Science ®Google Scholar
• CASELLAS P, BOURRIE BJ, GROS P, JANSEN FK: Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. 1. Biol. Chem. (1984) 259:9359–9364.
   Google Scholar
• FITZGERALD DJP, WALDMANN TA, WILLINGHAM MC, PASTAN I: Pseudomonas exotoxin-anti-TAC. 1 Chit Invest. (1984) 74:966–971.
   Google Scholar
• RAMAKRISHNAN S, HOUSTON LL: Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. Science (1983) 223:58–61.
   Web of Science ®Google Scholar
• RASO V, RITZ J, BASALA M, SCHLOSSMAN SF: Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing common acute lymphoblastic antigen. Cancer Res. (1982) 42:457–464.
   PubMed Web of Science ®Google Scholar
• MYERS CD, THORPE PE, ROSS WJC et al.: An immunotoxin with therapeutic potential in T cell leukemia: WT1 ricin A. Blood (1984) 63:1178–1185.
   PubMed Web of Science ®Google Scholar
• SEON BK: Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res. (1984) 44:259–264.
   PubMed Web of Science ®Google Scholar
• DURRANT LG, BYERS VS, SCANNON PJ et al.: Humoral immune responses to XMMC0-791-RTA immunotoxin in colorectal cancer patients. Clin. Exp. Immunot (1989) 75:258–264.
   PubMed Web of Science ®Google Scholar
• BLAKEY DC, THORPE PE: Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins. Scam/. I Rheumatol. (1988) 76(Suppl.):279–287.
   Google Scholar
• PASTAN I, FITZGERALD D: Recombinant toxins for cancer treatment. Science (1991) 254:1173–1177.
   PubMed Web of Science ®Google Scholar
• GILLILAND DG, STEPLEWSKI Z, COLLIER J, MITCHELL KF, CHANG TH, KOPROWSKI H: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA (1980) 77:4539–4543.
   PubMed Web of Science ®Google Scholar
• HOUSTON LL, NOWINSKI RC: Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against Thy 1.1 antigen. Cancer Res. (1981) 41:3913–3917.
   Google Scholar
• BLYTHMAN HE, CASELLAS P, GROS 0 etal.: Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells. Nature (1981) 290:145–146.
   Google Scholar
• VITETTA ES, KROLICK KA, UHR JW: Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunot Rev (1982) 62:159–183.
   PubMed Web of Science ®Google Scholar
• THORPE PE, ROSS WCJ: The preparation and cytotoxic properties of antibody-toxin conjugates. Immunot Rev (1982) 62:119–158.
   PubMed Web of Science ®Google Scholar
• KNOWLES PP, THORPE PE: Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal. Biochem. (1987) 160:440–443.
   PubMed Web of Science ®Google Scholar
• CUMBER AJ, FORRESTER JA, FOXWELL BM, ROSS WC, THORPE PE: Preparation of antibody-toxin conjugates. Meth. Enzymol. (1985) 112:207–225.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL, CAPPARELL NJ, ZAJDEL SH: Antitumor effects of antibody-diphteria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40.1 Natl. Cancer Inst. (1975) 55:473–477.
   Google Scholar
• BERNHARD MI, FOON KA, OELTMANN TN et at: Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphteria toxin A chain. Cancer Res. (1983) 43:4420–4428.
   PubMed Web of Science ®Google Scholar
• CHANG T, DAZORD A, NEVILLE DM, Jr: Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide complex. J Biol. Chem. (1977) 252:1515–1522.
   PubMed Web of Science ®Google Scholar
• DUMONTET C: Immunotherapy and cancer: the role of monoclonal antibodies. 1 OM: (1989) 126:682–686.
   Google Scholar
• YOULE RJ, COLOMABTTI M: Immunotoxins: monoclonal antibodies linked to toxic proteins for bone marrow transplantation and cancer therapy. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment JA Roth (Ed.), Futura Publishing Company, Inc., Mount Kisco, New York, USA (1986):173–213.
   Google Scholar
• TOLCHER AW, SUGARMAN S, GELMON KA et al.: Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. 1 Oncol. (1999) 17:478–484.
   Google Scholar
• MOLLER G (Ed.): Antibody carriers of drugs and toxins in tumor therapy. Immunol. Rev (1982) 62:1–216.
   Google Scholar
• BYERS VS, BALDWIN RW: Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology (1988) 65:329–335.
   PubMed Web of Science ®Google Scholar
• PIETERSZ GA, KRAUER K: Antibody-targeted drugs for the therapy of cancer. I Drug Target. (1994) 2:183–215.
   PubMed Web of Science ®Google Scholar
• REDWOOD WR, TOM TD, STRAND M: Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice. Cancer Res. (1984) 44:5681–5687.
   PubMed Web of Science ®Google Scholar
• FERENS JM, KROHN KA, BEAUMIER PL: High level iodination of monoclonal antibody fragments for radiotherapy. Nucl. Med. (1984) 25:367–370.
   Web of Science ®Google Scholar
• OOLDHAM RK: Custom-tailored drug immunoconjugates in cancer therapy. Mole. Blather. (1991) 3:148–162.
   PubMedGoogle Scholar
• ZHEN Y, PENG Z, DEND Y etal: Antitumor activity of immunoconjugates composed of boanmycin and monoclonal antibody. Chinese Med. Sciences J. (1994) 9:75–80.
   PubMedGoogle Scholar
• SIVAM GP, MARTIN PJ, REISFELD RA, MUELLER BM: Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res. (1995) 55:2352–2356.
   PubMed Web of Science ®Google Scholar
• YANO S, HANIBUCHI M, NISHIOKA Y et al.: Combined therapy with anti-P-glycoprotein antibody and macrophage colony-stimulating factor gene transduction for multiorgan metastases of multidrug-resistant human small cell lung cancer in NK cell-depleted SCID mice. Int. j Cancer (1999) 82:105–111.
   PubMed Web of Science ®Google Scholar
• SONE S, YANO S, HANIBUCHI M; et al.: Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice. Cancer Chemother. Pharmacol. (1999) 43:S26–S31.
   Google Scholar
• CLAUSS MA, JAIN RK: Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. (1990) 50:3487–3492.
   PubMed Web of Science ®Google Scholar
• DYKES PW, BRADWELL AR, CHAPMAN CE, VAUGHAN ATM: Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat. Rev (1987) 14:87–106.
   PubMed Web of Science ®Google Scholar
• SWABB EA, WET J, GULLINO PM: Diffusion and convection in normal and neoplastic tissues. Cancer Res. (1974) 34:2814–2822.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev (1987) 6:559–594.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules in the tumor interstitium: a review. Cancer Res. (1987) 47:3039–3051.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. j Natl. Cancer Inst. (1989) 81:570–576.
   PubMed Web of Science ®Google Scholar
• CHARY SR, JAIN RK: Direct measurements of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc. Nati Acad. Sci. USA (1989) 86:5385–5389.
   PubMed Web of Science ®Google Scholar
• LEVY RL, MILLER RA: Biological and clinical implications of lymphocyte hybridomas: Tumor therapy with monoclonal antibodies. Ann. Rev Med. (1983) 34:107–116.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, BEAUREGARD JC, SOBOL R.E. et al.: Lack of radioimmunodetection and complications associated with monoclonal anti-carcinoembryonic antigen: antibody crossreactivity with an antigen on circulating cells. Cancer Res. (1984) 44:2213–2218.
   Google Scholar
• DILLMAN RO, SHAWLER DL, DILLMAN JB: Therapy of chronic lymphocytic leukemia and cutaneous T cell lymphoma with T101 monoclonal antibody. J. Clin. °ilea (1984) 2:881–891.
   PubMed Web of Science ®Google Scholar
• FOON KA, SCHROFF RW, BUNN A et al.: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood (1984) 64:1085–1093.
   PubMed Web of Science ®Google Scholar
• SHAWLER DL, BARTHOLOMEW RIVI, SMITH LM, DILLMAN RO: Human immune response to multiple injections of murine monoclonal Ig. I Immunol. (1985) 135:1530–1535.
   PubMed Web of Science ®Google Scholar
• SCHROFF RW, FOON KA, BEATTY SM, OLDHAM RK, MORGAN AC: Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. (1985) 45:879–885.
   PubMed Web of Science ®Google Scholar
• STEVENSON FK, GEORGE AJ, GLENNIE MJ: Anti-idiotypic therapy of leukemias and lymphomas. Chem. Immunol. (1990) 48:126–166.
   PubMed Web of Science ®Google Scholar
• RITZ J, PESANDO JM, SALLAN SE et al.: Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood (1981) 58:141–152.
   PubMed Web of Science ®Google Scholar
• BALL ED, BERNIER GM, CORNWELL GG: Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia. Blood (1983) 62:1203–1210.
   PubMed Web of Science ®Google Scholar
• SEARS HF, HERLYN D, STEPLEWSKI Z, KOPROWSKI H: Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. _J. Biol. Resp. Modif (1984) 3:138–150.
   PubMed Web of Science ®Google Scholar
• SEARS HE HERLYN D, STEPLEWSKI Z, KOPROWSKI H: Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. (1985) 45:5910–5913.
   PubMed Web of Science ®Google Scholar
• BELLET D, BIDART JM, ROUGIER P, BOHUON C: Use of monoclonal antibodies in the treatment of cancer of the pancreas: towards new progress? Bull. Cancer (1990) 77:283–288.
   Google Scholar
• OLDHAM RK, FOON KA, MORGAN AC etal.: Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. j Chi]. Omni (1984) 2:1235–1244.
   Google Scholar
• HOUGHTON AN, GORDON-CURDO C, EISINGER M: Differentiation antigens of melanoma and melanocytes. Int. Rev Exp. Pathol. (1986) 28:217–248.
   PubMedGoogle Scholar
• GOODMAN GE, BEAUMIER P, HELLSTROM I, FERNYHOUGH B, ELLSTROM KE: Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. j Clin Omni (1985) 3:340–352.
   PubMed Web of Science ®Google Scholar